- Home
- PLTR vs AZN Comparison
PLTR vs AZN Comparison
Compare PLTR & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLTR | AZN |
|---|---|---|
| Founded | 2003 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | 96100 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.0B | 316.4B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PLTR | AZN |
|---|---|---|
| Price | $135.40 | $185.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 1 |
| Target Price | ★ $192.83 | N/A |
| AVG Volume (30 Days) | ★ 34.1M | 1.7M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.73% |
| EPS Growth | ★ 231.58 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $4,475,446,000.00 | N/A |
| Revenue This Year | $65.66 | $10.34 |
| Revenue Next Year | $42.35 | $6.43 |
| P/E Ratio | $416.59 | ★ $31.91 |
| Revenue Growth | ★ 56.18 | N/A |
| 52 Week Low | $122.68 | $68.62 |
| 52 Week High | $207.46 | $212.71 |
Technical Indicators
Market Signals| Indicator | PLTR | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 49.81 |
| Support Level | $127.13 | $180.98 |
| Resistance Level | $152.85 | $191.50 |
| Average True Range (ATR) | 6.72 | 3.00 |
| MACD | 0.27 | -0.05 |
| Stochastic Oscillator | 9.99 | 61.27 |
Price Performance
Historical ComparisonAbout PLTR Palantir Technologies Inc.
Palantir is an artificial intelligence, analytics, and automated decision-making company that leverages data to drive efficiency across its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The company was founded in 2003 and went public in 2020.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.